港股異動 | 康希諾生物-B升超10%,科創板7月31日開啟申購
uSMART友信智投7月30日消息,週四港股,康希諾生物-B高開高走,截至10:58分,康希諾生物-B升10.41%,報271.8港元。
7月30日,康希諾生物-B在港交所發佈公告稱,於2020年7月28日完成向詢價對象進行的初步詢價後,公司將發行2480萬股A股,發行價格為每股A股人民幣209.71元,7月31日將正式開始申購。
康希諾是一家致力於研發、生產與銷售的創新型疫苗企業,2019年3月登陸港股,目前有望成為A股市場最受矚目的“新冠疫苗第一股”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.